Physician profile
Gary D Wendell
NPI 1497868848
$3,727.47
in general payments reported to CMS, 2019-2025
25 companies · $92.83 in 2025
The $92.83 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $513 · 2021: $306 · 2022: $734 · 2023: $566 · 2024: $448 · 2025: $92.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $963.01 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $556.07 | 2019-2024 | Breztri, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.89 | 2019-2022 | |
| Philips North America LLC | $296.84 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $198.81 | 2019-2024 | Yupelri |
| Insmed, INC. | $180.92 | 2019-2023 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $165.88 | 2019-2024 | Dupixent |
| Genzyme Corporation | $126.61 | 2019-2024 | |
| Pfizer INC. | $120.63 | 2019-2022 | |
| Allergan, INC. | $119.61 | 2019-2020 | |
| Genentech USA, INC. | $90.84 | 2019 | |
| Abbvie INC. | $87.79 | 2021-2022 | |
| Grifols USA, LLC | $79.77 | 2019-2025 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $48.20 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $36.05 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $34.63 | 2023 | Wakix |
| Axsome Therapeutics, INC. | $33.23 | 2023 | Sunosi |
| Merck Sharp & Dohme LLC | $32.52 | 2019-2020 | |
| Tactile Systems Technology INC | $25.86 | 2024 | Entre Plus, Flexitouch Plus |
| Sunovion Pharmaceuticals INC. | $24.93 | 2020 | |
| Janssen Pharmaceuticals, INC | $22.49 | 2020 | |
| Mallinckrodt Enterprises LLC | $20.76 | 2019 | |
| Gilead Sciences, INC. | $19.98 | 2021 | |
| Circassia INC. | $16.35 | 2020 | |
| Advanced Respiratory, INC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Wendell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.